0000899243-20-020565.txt : 20200728
0000899243-20-020565.hdr.sgml : 20200728
20200728181109
ACCESSION NUMBER: 0000899243-20-020565
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200728
FILED AS OF DATE: 20200728
DATE AS OF CHANGE: 20200728
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000899866
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 201055056
BUSINESS ADDRESS:
STREET 1: 121 SEAPORT BOULEVARD
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 4752302596
MAIL ADDRESS:
STREET 1: 121 SEAPORT BOULEVARD
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER NAME:
FORMER CONFORMED NAME: ALEXION PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-28
1
0001693011
Inozyme Pharma, Inc.
INZY
0000899866
ALEXION PHARMACEUTICALS, INC.
121 SEAPORT BOULEVARD
BOSTON
MA
02210
0
0
1
0
Common Stock
2020-07-28
4
C
0
1109910
A
1109910
D
Series A-2 Convertible Preferred Stock
2020-07-28
4
C
0
8294360
0.00
D
Common Stock
1109910
0
D
On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
/s/ Douglas Barry, as Assistant Secretary of Alexion Pharmaceuticals, Inc.
2020-07-28